Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
API
0
FDF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 2-((1-ethoxycarbony)-3-phenylpropylamino-1-oxopropyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid
2. Fempress
3. Moex
4. Moexipril
5. Perdix
6. Rs 10085
7. Rs-10085
8. Univasc
1. Moexipril Hcl
2. 82586-52-5
3. Univasc
4. Spm 925
5. Ci 925
6. Moexipril Hydrochloride [usan]
7. Moexipril (hydrochloride)
8. Spm-925
9. Ci-925
10. Rs-10085-197
11. Q1umg3uh45
12. Rs-10085
13. Dsstox_cid_24267
14. Dsstox_rid_80137
15. Dsstox_gsid_44267
16. (3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid, 2-ethyl Ester, Monohydrochloride
17. (3s)-2-[(2s)-2-[[(1s)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic Acid Hydrochloride
18. (3s)-2-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic Acid;hydrochloride
19. 3-isoquinolinecarboxylic Acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, Monohydrochloride, (3s-(2(r*(r*)),3r*))-
20. Unii-q1umg3uh45
21. Cas-82586-52-5
22. Femipres
23. Primoxil
24. Rs 10085-197
25. (3s)-2-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenyl-d5-propyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid Hydrochloride
26. Univasc (tn)
27. Moexipril Hcl- Bio-x
28. Ncgc00167834-01
29. Rs 10085
30. 5-hydroxy-2-iodobenzoicacid
31. Schembl40877
32. Mls003882580
33. Moexipril Hydrochloride (usp)
34. Chebi:6961
35. Chembl1200534
36. Dtxsid7044267
37. Hy-b0378a
38. Moexipril Hydrochloride [mi]
39. Tox21_112590
40. S2079
41. Akos016340373
42. Tox21_112590_1
43. Bs-1007
44. Ccg-269939
45. Moexipril Hydrochloride [mart.]
46. Moexipril Hydrochloride [vandf]
47. Moexipril Hydrochloride [usp-rs]
48. Moexipril Hydrochloride [who-dd]
49. Ncgc00263546-01
50. 3-isoquinolinecarboxylic Acid, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, Monohydrochloride, (3s-(2(r*(r*)),3r*))-
51. Bm164604
52. Smr002533645
53. Moexipril Hydrochloride [orange Book]
54. Sw219263-1
55. D00623
56. Moexipril Hydrochloride [usp Monograph]
57. Moexipril Hydrochloride, Powder, >=98% (hplc)
58. Uniretic Component Moexipril Hydrochloride
59. 586m525
60. A846428
61. Moexipril Hydrochloride Component Of Uniretic
62. Q27286898
63. Moexipril Hydrochloride, United States Pharmacopeia (usp) Reference Standard
64. (3s)-2-((2s)-2-(((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid Hydrochloride
65. (s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-l-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride
66. (s)-2-((s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride
67. 2-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid Hydrochloride
Molecular Weight | 535.0 g/mol |
---|---|
Molecular Formula | C27H35ClN2O7 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 12 |
Exact Mass | 534.2132792 g/mol |
Monoisotopic Mass | 534.2132792 g/mol |
Topological Polar Surface Area | 114 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 742 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Moexipril hydrochloride |
Drug Label | Moexipril hydrochloride, the hydrochloride salt of moexipril, has the empirical formula C27H34N2O7.HCl and a molecular weight of 535.04. It is chemically described as [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1... |
Active Ingredient | Moexipril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 15mg |
Market Status | Prescription |
Company | Teva; Apotex; Glenmark Generics; Paddock |
2 of 6 | |
---|---|
Drug Name | Uniretic |
PubMed Health | Moexipril/Hydrochlorothiazide (By mouth) |
Drug Classes | ACE Inhibitor/Thiazide Combination, Antihypertensive, Cardiovascular Agent |
Active Ingredient | Hydrochlorothiazide; moexipril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 25mg; 15mg; 12.5mg |
Market Status | Prescription |
Company | Ucb |
3 of 6 | |
---|---|
Drug Name | Univasc |
PubMed Health | Moexipril (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Renal Protective Agent |
Drug Label | univasc (moexipril hydrochloride), the hydrochloride salt of moexipril, has the empirical formula C27H34N2O7HCl and a molecular weight of 535.04. It is chemically described as [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-... |
Active Ingredient | Moexipril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 15mg |
Market Status | Prescription |
Company | Ucb |
4 of 6 | |
---|---|
Drug Name | Moexipril hydrochloride |
Drug Label | Moexipril hydrochloride, the hydrochloride salt of moexipril, has the empirical formula C27H34N2O7.HCl and a molecular weight of 535.04. It is chemically described as [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1... |
Active Ingredient | Moexipril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 15mg |
Market Status | Prescription |
Company | Teva; Apotex; Glenmark Generics; Paddock |
5 of 6 | |
---|---|
Drug Name | Uniretic |
PubMed Health | Moexipril/Hydrochlorothiazide (By mouth) |
Drug Classes | ACE Inhibitor/Thiazide Combination, Antihypertensive, Cardiovascular Agent |
Active Ingredient | Hydrochlorothiazide; moexipril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 25mg; 15mg; 12.5mg |
Market Status | Prescription |
Company | Ucb |
6 of 6 | |
---|---|
Drug Name | Univasc |
PubMed Health | Moexipril (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Renal Protective Agent |
Drug Label | univasc (moexipril hydrochloride), the hydrochloride salt of moexipril, has the empirical formula C27H34N2O7HCl and a molecular weight of 535.04. It is chemically described as [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-... |
Active Ingredient | Moexipril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 15mg |
Market Status | Prescription |
Company | Ucb |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Angiotensin-Converting Enzyme Inhibitors
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)
Related Excipient Companies
Excipients by Applications
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A moexipril hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of moexipril hydrochloride, including repackagers and relabelers. The FDA regulates moexipril hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. moexipril hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of moexipril hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A moexipril hydrochloride supplier is an individual or a company that provides moexipril hydrochloride active pharmaceutical ingredient (API) or moexipril hydrochloride finished formulations upon request. The moexipril hydrochloride suppliers may include moexipril hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of moexipril hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A moexipril hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of moexipril hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of moexipril hydrochloride DMFs exist exist since differing nations have different regulations, such as moexipril hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A moexipril hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. moexipril hydrochloride USDMF includes data on moexipril hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The moexipril hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of moexipril hydrochloride suppliers with USDMF on PharmaCompass.
A moexipril hydrochloride written confirmation (moexipril hydrochloride WC) is an official document issued by a regulatory agency to a moexipril hydrochloride manufacturer, verifying that the manufacturing facility of a moexipril hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting moexipril hydrochloride APIs or moexipril hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a moexipril hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of moexipril hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing moexipril hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for moexipril hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture moexipril hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain moexipril hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a moexipril hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of moexipril hydrochloride suppliers with NDC on PharmaCompass.
moexipril hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of moexipril hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right moexipril hydrochloride GMP manufacturer or moexipril hydrochloride GMP API supplier for your needs.
A moexipril hydrochloride CoA (Certificate of Analysis) is a formal document that attests to moexipril hydrochloride's compliance with moexipril hydrochloride specifications and serves as a tool for batch-level quality control.
moexipril hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each moexipril hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
moexipril hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (moexipril hydrochloride EP), moexipril hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (moexipril hydrochloride USP).
LOOKING FOR A SUPPLIER?